close
close

Unicycive Therapeutics (UNCY) Reaffirmed at HC Wainwright

Unicycive Therapeutics (UNCY) Reaffirmed at HC Wainwright


HC Wainwright reiterates buy rating on stock Single Ring Therapeutics (NASDAQ:UNCYFree Report) In a report published on Wednesday, Benzinga According to reports, HC Wainwright’s current target price for the stock is $4.50.

Other equities analysts have also recently issued reports on the company. Benchmark reiterated a speculative buy rating and issued a $3.00 price target on shares of Unicycive Therapeutics in a research note on Friday, May 31. Piper Sandler reported on Unicycive Therapeutics in a research report on Thursday, April 4. They issued an overweight rating and a $9.00 target price for the company. Four investment analysts have rated the stock with a buy rating and one has given the company a strong buy rating. According to data from MarketBeat.com, Unicycive Therapeutics has an average Buy rating and a consensus target price of $5.63.

View Our Latest Report on Unicycive Therapeutics

Unicyclic Therapeutics Up 2.1%

Unicyclic Therapeutics stock It opened at $0.49 on Wednesday. Unicycive Therapeutics has a 52-week low of $0.34 and a 52-week high of $1.82. The stock has a market cap of $18.27 million, a P/E ratio of -0.41 and a beta of 2.39. The stock’s 50-day moving average is $0.79 and its 200-day moving average is $1.05.

Single Ring Therapeutics (NASDAQ:UNCYGet a Free Report) released its latest quarterly earnings data on Monday, May 13. The company reported ($0.27) EPS for the quarter, missing analysts’ ($0.18) consensus estimates of ($0.09). As a group, equities analysts are forecasting that Unicycive Therapeutics will post -0.82 earnings per share for the current fiscal year.

Hedge Funds Explain Their Views on Unicycive Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of UNCY. Virtu Financial LLC purchased a new stake in Unicycive Therapeutics shares in the 1st quarter worth approximately $36,000. Rosalind Advisors Inc. purchased a new stake in Unicycive Therapeutics shares in the 1st quarter worth $2,594,000. Finally, BVF Inc. IL increased its stake in Unicycive Therapeutics by 70.5% in the 1st quarter. BVF Inc. IL now owns 3,611,601 shares of the company worth $4,984,000 after purchasing an additional 1,493,462 shares in the last quarter. 40.42% of the shares are currently held by institutional investors and hedge funds.

About Unicyclic Therapeutics

(Get a Free Report)

Biotechnology company Unicycive Therapeutics, Inc. is busy developing new treatments for kidney diseases in the United States. It is developing Renazorb for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis and UNI 494, which is in Phase 1 clinical trials for the treatment of acute kidney injury.

Further reading



Get News and Ratings for Unicycive Therapeutics Daily – Enter your email address below to subscribe to MarketBeat.com’s FREE daily email newsletter to receive a concise daily summary of the latest news and analyst ratings for Unicycive Therapeutics and related companies.